|
|
|
| Analysis of Megadose Meropenem combined with Sulbactam treating pneumonia of multidrug resistant Acinetobacter Bauman |
| CHEN Jia-wei |
| Department of Critical Care Medicine,Center Hospital in Chaozhou City of Guangdong Province,Chaozhou 521000,China |
|
|
|
|
Abstract ObjectiveTo explore the effect of Megadose Meropenem combined with Sulbactam treating pneumonia of multidrug resistant Acinetobacter Bauman.MethodsThe clinical data of 65 patients with pneumonia of multidrug resistant Acinetobacter Bauman treated in our hospital from June 2011 to August 2016 were selected to analyze.They were divided into two groups according to different therapeutic measures.In the control group(n=30),patients were treated by common dose of Meropenem(1.0 g)combined with Sulbactam,while in the observation group(n=35),high-dose of Meropenem(2.0 g)combined with Sulbactam was adopted.Patients were treated for five days.The plasma indexes(PCT,CRP), white blood cell count,clinical effect,and adverse reaction before and after therapy in the two groups were compared.ResultsThe difference of PCT,CRP,WBC count of the two groups before treatment were not statistically significant(P> 0.05),after treatment,PCT,CRP,WBC count in two groups were lower than that before treatment,and PCT,CRP,WBC count after treatment in the observation group were lower than those of the control group,the differences were statistically significant(P<0.05).The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).There was no significant difference in the incidence rate of adverse reactions between the two groups (P>0.05).ConclusionThe clinical effect of Megadose Meropenem combined with Sulbactam treating pneumonia of multidrug resistant Acinetobacter Bauman caused by drug resistant Acinetobacter Bauman is obvious,and it has no obvious adverse reactions,it is worthy of clinical promotion and application.
|
|
|
|
|
|
| [1] |
王贻，伏冉，郑玉龙，等.耐碳青霉烯类鲍曼不动杆菌医院获得性肺炎危险因素和死亡率分析[J].临床肺科杂志，2016，21（5）：784-788.
|
| [3] |
费东生，曹延会，南川川，等.耐碳青霉烯类抗生素鲍曼不动杆菌呼吸机相关肺炎的危险因素[J].中国老年学杂志，2013，33（20）：4945-4947.
|
| [2] |
Arvaniti K，Lathyris D，Ruimy R，et al．The importance of colonization pressure in multiresistant Acinetobacter baumanniiacquisitioninaGreekintensivecareunit[J].CritCare，2012，16（3）：R102．
|
| [4] |
Randrianirina F，Vaillant L，Ramarokoto CE，et al．Antimicrobial resistance in pathogens causing nosocomial infections in surgery and intensive care units of two hospitals in Antananarivo，Madagascar[J].J Infect Dev Ctries,2010，4（2）：74-82.
|
| [5] |
陈佰义，何礼贤，胡必杰，等．中国鲍曼不动杆菌感染诊治与防控专家共识[J].中国医学杂志，2012，92（8）：76-85．
|
| [6] |
Ye JJ，Huang CT，Shie SS，et al.Multidrug resistant acinetobacter baumannii：risk factors for appearance of imipenem resistant strains on patients formerly with susceptible strains[J]. PLoS One，2010，5（4）：9947.
|
| [7] |
王韧韬，余丹阳.碳青霉烯类抗生素联合舒巴坦治疗耐药鲍曼不动杆菌导致的医院获得性肺炎[J].军医进修学院学报，2011，32（7）：687-689.
|
| [8] |
PlayfordEG，CraigJC，IredellJR.Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients：risk factors for acquisition，infection and their consequences[J].J Hosp Infect，2007，65（3）：204-211.
|
| [9] |
卢健聪，蔡绍曦，耿穗娜，等.耐碳青霉烯鲍曼不动杆菌医院获得性肺炎的危险因素及预后分析[J].中国呼吸与危重监护杂志，2009，8（1）：24-27.
|
| [10] |
谢志杰，张丽娟，宋国斌.头孢哌酮/舒巴坦联合纤维支气管镜治疗老年多重耐药鲍曼不动杆菌肺炎的研究[J].河北医药，2016，38（21）：3281-3283.
|
| [11] |
陈海红，李华茵，何礼贤，等.耐碳青霉烯类抗生素鲍曼不动杆菌医院获得性肺炎病例分析[J].中国感染与化疗杂志，2010，10（2）：94-99.
|
| [12] |
李安，陈丰哲，王正，等.西他沙星、头孢哌酮/舒巴坦和多粘菌素E单药及联合用药对泛耐药鲍曼不动杆菌的抗菌活性[J].山东大学学报（医学版），2016，54（11）：7-10.
|
| [13] |
张丽娟，马玲，仝会坤，等.舒巴坦在治疗耐碳青霉烯鲍曼不动杆菌医院获得性肺炎中的作用[J].河北医药，2012，34（23）：3647-3648.
|
| [14] |
杨军辉，李佳，李宁，等.多粘菌素E、替加环素及比阿培南联合舒巴坦对多重耐药鲍曼不动杆菌肺炎治疗的对比研究[J].陕西医学杂志，2016，45（6）：756-757.
|
| [15] |
裴红莎，刘宝来，聂晓奇，等.磷霉素和头孢哌酮/舒巴坦钠序贯疗法治疗颅内多重耐药鲍曼不动杆菌感染的临床分析[J].中国临床神经外科杂志，2016，21（4）：232-233.
|
| [16] |
于亮，王梅.三种碳青霉烯类抗菌药物联用头孢哌酮舒巴坦对耐碳青霉烯鲍曼不动杆菌的抗菌活性分析[J].中华试验和临床感染病杂志，2013，7（6）：893-896.
|
| [17] |
李建华，王玉明，戴路明，等.碳青霉烯类抗菌药物对大肠埃希菌、肺炎克雷伯菌、铜绿假单胞菌、鲍曼不动杆菌的防突变浓度研究[J].中国医院药学杂志，2016，36（2）：130-135.
|
|
|
|
